美国双胍类与磺脲类降糖药暴露的鉴别特征
本研究基于美国国家毒物数据系统(National Poison Data System)进行六年回顾性队列分析,纳入6183例双胍类和磺脲类降糖药暴露病例,采用二元逻辑回归识别临床效应。双胍类和磺脲类暴露患者平均年龄分别为39.27±28.91岁和28.91±30.41岁。磺脲类暴露最常见于无意暴露,而双胍类暴露常为有意摄入;双胍类暴露后常见轻度结局,磺脲类暴露后常见中度结局。磺脲类暴露较双胍类更少出现腹痛、代谢性酸中毒、腹泻、恶心、呕吐和肌酐升高,但更易引起头晕或眩晕、震颤、嗜睡或昏睡、激越、出汗和低血糖。该研究首次利用全国范围数据描述两类降糖药中毒暴露的鉴别临床特征。
要点
- 磺脲类暴露更易引起低血糖、出汗、震颤、头晕或眩晕、激越、嗜睡或昏睡,接诊时需优先监测血糖。
- 双胍类暴露更易引起腹痛、代谢性酸中毒、腹泻、恶心、呕吐和肌酐升高,需关注酸中毒和肾功能。
- 磺脲类暴露最常见于无意暴露,双胍类暴露常为有意摄入,提示双胍类暴露患者需评估自杀意图。
- 双胍类暴露后常见轻度结局,磺脲类暴露后常见中度结局。
- 双胍类和磺脲类暴露患者平均年龄分别为39.27±28.91岁和28.91±30.41岁。
适用人群与场景
- 美国国家毒物数据系统(National Poison Data System)中6183例双胍类和磺脲类降糖药暴露病例。
红旗征与不能漏的情况
- 磺脲类暴露更易引起低血糖、出汗、震颤、头晕或眩晕、激越、嗜睡或昏睡。
- 双胍类暴露更易引起腹痛、代谢性酸中毒、腹泻、恶心、呕吐和肌酐升高。
研究设计与关键结果
- 研究类型:六年回顾性队列分析,基于美国国家毒物数据系统(National Poison Data System),纳入6183例双胍类和磺脲类暴露,采用二元逻辑回归识别临床效应。
- 双胍类和磺脲类暴露患者平均年龄分别为39.27±28.91岁和28.91±30.41岁。
- 磺脲类暴露最常见于无意暴露,双胍类暴露常为有意摄入。
- 双胍类暴露后常见轻度结局,磺脲类暴露后常见中度结局。
- 磺脲类暴露较双胍类更少出现腹痛、代谢性酸中毒、腹泻、恶心、呕吐和肌酐升高。
- 磺脲类暴露较双胍类更易引起头晕或眩晕、震颤、嗜睡或昏睡、激越、出汗和低血糖。
证据类型、等级与局限
- 证据类型:基于美国国家毒物数据系统(National Poison Data System)的六年回顾性队列分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,磺脲类暴露常见于无意暴露,双胍类暴露常见于有意暴露;磺脲类毒性更易引起激越、头晕或眩晕、震颤、出汗和低血糖,而双胍类暴露引起腹痛、酸中毒、腹泻、恶心、呕吐和肌酐升高。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Biguanides and sulfonylureas are anti-hyperglycemic drugs commonly used in the United States. Poisoning with these drugs may lead to serious consequences. The diagnosis of biguanide and sulfonylurea poisoning is based on history, clinical manifestations, and laboratory studies.
METHODS: This study is a six-year retrospective cohort analysis based on the National Poison Data System. Clinical effects of 6183 biguanide and sulfonylurea exposures were identified using binary logistic regression.
RESULTS: The mean age of patients with biguanide and sulfonylurea exposure was 39.27 ± 28.91 and 28.91 ± 30.41 years, respectively. Sulfonylurea exposure is most commonly seen via unintentional exposure, while biguanide exposure frequently occurs as a result of intentional ingestion. Minor and moderate outcomes commonly developed following biguanide and sulfonylurea exposure, respectively. Sulfonylurea exposure was less likely to develop clinical effects abdominal pain, metabolic acidosis, diarrhea, nausea, vomiting, and elevated creatinine than patients ingesting biguanides. However, sulfonylurea exposure was more likely to cause dizziness or vertigo, tremor, drowsiness or lethargy, agitation, diaphoresis, and hypoglycemia.
CONCLUSIONS: Our study is the first to use a wide range of national data to describe the clinical characteristics that differentiate the toxicologic exposure to biguanides and sulfonylureas. Sulfonylurea exposure is commonly seen via unintentional exposure, while metformin exposure is frequently seen via intentional exposure. Sulfonylurea toxicity is more likely to cause agitation, dizziness or vertigo, tremor, diaphoresis, and hypoglycemia, while metformin exposure induces abdominal pain, acidosis, diarrhea, nausea, vomiting, and elevated creatinine.
参考来源
- Mehrpour O, Saeedi F, Hoyte C, et al. Distinguishing characteristics of exposure to biguanide and sulfonylurea anti-diabetic medications in the United States. Am J Emerg Med. 2022. PMID: 35398707. doi:10.1016/j.ajem.2022.03.023
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。